Private Equity

Aligos Therapeutics is using strategic stock grants to lure top talent. Is this a savvy growth play or a creeping cost for shareholders? We break it down.

Acadia's new powder form of the only Rett syndrome drug offers families vital choice, easing daily care and showing the power of patient-led innovation.

With full control of a prized Turkish zinc mine, Pasinex bets big on a 1,000-meter deep dig. Can this capital-intensive play pay off in a shifting market?

With its fourth acquisition under ZCG ownership, Unimed is consolidating the fragmented maritime health market, leveraging tech to create a dominant platform.

With over 123 million displaced, refugee camps are now de facto cities. Temporary water solutions are fueling disease, making the case for permanent fixes.

As Uxin prepares to report Q3 results, all eyes are on its ambitious superstore strategy and whether it can drive profitability in a complex market.

PSH continues its multi-billion dollar share repurchase strategy to tackle its stubborn stock discount. What does this mean for the fund and its future targets?

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

Yum China's massive share buyback isn't just about rewarding investors. It's a calculated move signaling financial dominance in a complex market.

Centrus Energy is building a key Ohio facility, the first step in a multi-billion dollar plan to end US reliance on Russian uranium for next-gen reactors.

The private capital market leader's latest user-voted award reveals a major trend: authentic customer feedback is the new currency in high-stakes investing.

AMC's key governance reforms failed despite 90% voter support, stymied by low turnout. Meanwhile, a major share increase passed. What does this mean?

Erie Indemnity boosts its dividend by 7.1%, but a deeper look reveals a unique and legally challenged fee structure driving its profitability.

Costco's Q1 results reveal more than just profit; a massive digital leap and resilient membership model signal a major shift in the future of retail.

Zoetis boosts its dividend by 6%, but what does this move signal about the company's financial health and the booming global animal care market?

BrightView Holdings declared its eighth straight cash dividend, a move signaling financial discipline even as it navigates revenue challenges and stock volatility.

Tenaya Therapeutics seeks fresh capital to advance its heart disease pipeline, but the offering's structure raises dilution questions for investors.

Excelerate Energy signals deep confidence with a new $75M share buyback, balancing shareholder rewards with an ambitious global expansion in the LNG market.

Argan's repeated dividend hikes and record backlog reflect deep confidence, positioning it to capitalize on surging demand for critical energy infrastructure.

A rejected $307M Danone offer and claims of poor governance fuel a bitter proxy fight at Lifeway Foods, pitting CEO against her largest shareholder—her brother.